Oliveira et al. (31) demonstrated that direct recognition by CD4+ T cells was restricted to 2 melanomas with extremely high tumor mutational burdens, suggesting that this phenotype may confer additional necessary alterations permitting MHC-II presentation of tumor antigens. This evidence concerns the gene CD4 and melanoma.